Production , purification and preparation of various candidiate vaccines

该股继续致力于研制针对福氏志贺氏菌和炭疽芽孢杆菌的新疫苗，产品目前正在进行临床试验。建立了重组铜绿假单胞菌外毒素A的生产和纯化工艺，并获得了克数蛋白。该蛋白通过与细菌多糖结合，用于制备结合疫苗。建立了从炭疽芽孢杆菌中获得灭活保护性抗原的生产和纯化工艺，并获得了克数的蛋白质。这种炭疽疫苗正在使用几种不同的配方进行研究：甲醛处理、甲醛与明矾处理、明矾单独处理和未经处理的蛋白质。此外，目前正在准备将保护性抗原与炭疽胶囊结合进行临床研究。制备了重组艰难梭菌毒素a和重组白喉类毒素等蛋白，并对其进行了偶联评价。

The Unit continued work on the development of new vaccines against Shigella flexneri and Bacillus anthracis, products are currently in clinical trials. A production and purification procedures for recombinant Pseudomonas aeruginosa exotoxin A was developed and gram quantities of the protein were made. This protein was used for the preparation of a conjugated vaccine by conjugating the protein to the bacterial polysaccharide. A production and purification procedure for obtaining inactivated protective antigen from Bacillus anthracis was established and gram quantities of this protein were made. This anthrax vaccine is being studied by using several different formulations: formaldehyde treated, formaldehyde treated with alum, alum alone, and untreated protein. Additionally, conjugating the protective antigen with the anthrax capsule is currently being prepared for clinical studies. Several proteins were prepared for evaluation as a potential candidate for conjugation, among them recombinant toxin A of Clostridium difficle and recombinant diphtheria toxoid. The Biotechnology Unit also produced large quantities of experimental recombinant malaria transmission blocking vaccine from Pichia pastoris, this work was done in collaboration with the Malaria Vaccine Development Unit of NIAID. The Unit was also involved in improving the production procedure of plasmid DNA, evaluating different host microorganisms. Significant increase in specific production was achieved by replacing the current E. coli production strain with a genetically modified strain.